Quest Diagnostics (DGX) Tops Q2 EPS by 5c; offers guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.62, $0.05 better than the analyst estimate of $2.57. Revenue for the quarter came in at $2.76 billion versus the consensus estimate of $2.73 billion.

GUIDANCE:

Quest Diagnostics sees FY2025 EPS of $9.63-$9.83, versus the consensus of $9.70. Quest Diagnostics sees FY2025 revenue of $10.8-10.92 billion, versus the consensus of $10.795 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c